Profile data is unavailable for this security.
About the company
PureTech Health plc is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has developed 27 therapeutics and therapeutic candidates, including two (Plenity and EndeavorRx) that have received both United States (US) Food and Drug Administration (FDA) clearance and European marketing authorization. The Company's pipeline includes LYT-100, LYT-200, LYT-300, LYT-310 and LYT-503/IMB-150. LYT-100 (deupirfenidone) is being advanced for the potential treatment of conditions involving inflammation and fibrosis. It is developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. LYT-300 is an oral prodrug of allopregnanolone, which is being advanced for the potential treatment of anxiety disorders and postpartum depression.
- Revenue in GBP (TTM)9.42m
- Net income in GBP-37.73m
- Incorporated2015
- Employees111.00
- LocationPureTech Health PLC6 Tide Street, Suite 400BOSTON 02210United StatesUSA
- Phone+1 (617) 482-2333
- Fax+1 (617) 482-3337
- Websitehttps://puretechhealth.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Creo Medical Group PLC | 29.23m | -25.10m | 126.88m | 279.00 | -- | 1.78 | -- | 4.34 | -0.1139 | -0.1139 | 0.126 | 0.1966 | 0.3318 | 1.87 | 4.14 | 102,926.10 | -28.49 | -- | -34.24 | -- | 48.11 | -- | -85.87 | -- | 3.45 | -- | 0.1177 | -- | 7.98 | -- | -9.52 | -- | -- | -- |
Animalcare Group Plc | 74.35m | 1.20m | 130.43m | 220.00 | 109.76 | 1.67 | 14.80 | 1.75 | 0.0198 | 0.0198 | 1.22 | 1.30 | 0.6608 | 2.63 | 5.54 | -- | 1.07 | 0.3272 | 1.30 | 0.3866 | 58.30 | 53.62 | 1.61 | 0.5484 | 1.05 | 5.44 | 0.0701 | 599.95 | 3.82 | 0.5138 | -38.98 | -- | -11.79 | 2.59 |
Allergy Therapeutics plc | 53.26m | -50.22m | 135.84m | 635.00 | -- | 5.13 | -- | 2.55 | -0.0266 | -0.0266 | 0.017 | 0.0056 | 0.7571 | 2.21 | 4.92 | 83,870.87 | -71.39 | -11.59 | -102.10 | -15.15 | 52.54 | 70.08 | -94.29 | -11.78 | 0.9281 | -7.93 | 0.2713 | -- | -18.11 | -2.71 | -212.65 | -- | 16.41 | -- |
4Basebio PLC | 354.00k | -6.28m | 137.02m | -- | -- | 38.65 | -- | 387.05 | -0.5094 | -0.5094 | 0.0287 | 0.2769 | 0.0296 | 0.3977 | 4.88 | -- | -52.42 | -- | -60.21 | -- | 80.51 | -- | -1,772.60 | -- | 3.28 | -40.29 | 0.6683 | -- | -20.71 | -- | -59.20 | -- | -- | -- |
Avacta Group Plc | 16.03m | -42.08m | 162.65m | 120.00 | -- | 5.49 | -- | 10.15 | -0.1605 | -0.1633 | 0.0606 | 0.0826 | 0.2406 | 4.50 | 2.38 | 133,541.70 | -63.18 | -- | -119.23 | -- | 54.40 | -- | -262.60 | -- | 0.6603 | -1.66 | 0.6913 | -- | 228.22 | -- | -49.92 | -- | -- | -- |
Alliance Pharma plc | 170.05m | -7.06m | 189.14m | 249.00 | -- | 0.6826 | 60.39 | 1.11 | -0.0131 | -0.0131 | 0.3145 | 0.5127 | 0.3202 | 2.88 | 4.40 | 682,927.70 | -1.33 | 2.64 | -1.47 | 2.95 | 57.58 | 63.38 | -4.15 | 8.35 | 1.38 | 2.18 | 0.31 | 53.41 | 2.58 | 10.50 | -87.21 | -49.62 | -25.78 | 5.94 |
hVIVO PLC | 56.04m | 16.12m | 193.91m | 274.00 | 12.18 | 5.65 | 10.30 | 3.46 | 0.0234 | 0.0234 | 0.0817 | 0.0505 | 0.8327 | -- | 4.08 | 204,536.50 | 23.94 | -0.643 | 46.27 | -1.29 | -- | -- | 28.75 | -0.765 | 1.47 | -- | 0.2674 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
Oxford BioMedica plc | 119.02m | -61.63m | 218.50m | 891.00 | -- | 1.23 | -- | 1.84 | -0.6389 | -0.6389 | 1.23 | 1.78 | 0.2743 | 4.67 | 3.09 | 131,662.60 | -16.18 | -4.45 | -21.95 | -5.69 | 46.20 | 53.90 | -58.97 | -8.16 | 3.07 | -9.24 | 0.3635 | -- | -1.97 | 30.08 | -305.97 | -- | 52.60 | -- |
Bioventix PLC | 13.60m | 8.67m | 233.58m | 16.00 | 27.41 | 20.43 | 26.58 | 17.18 | 1.63 | 1.63 | 2.56 | 2.19 | 1.09 | 1.53 | 2.54 | 849,780.60 | 69.72 | 56.43 | 79.03 | 61.01 | 93.75 | 92.64 | 63.73 | 65.08 | 6.69 | -- | 0.00 | 84.49 | 9.36 | 7.93 | 9.10 | 8.13 | -37.12 | 20.03 |
Niox Group PLC | 36.80m | 9.50m | 284.09m | 85.00 | 31.79 | 3.15 | 20.44 | 7.72 | 0.0211 | 0.0238 | 0.0819 | 0.2136 | 0.3874 | 2.31 | 6.13 | 432,941.20 | 10.00 | -2.41 | 10.57 | -2.90 | 72.01 | 70.87 | 25.82 | -11.46 | 3.99 | -- | 0.013 | -- | 17.57 | -5.29 | -32.62 | -- | -5.59 | -- |
Puretech Health PLC | 9.42m | -37.73m | 573.04m | 111.00 | -- | 1.49 | -- | 60.83 | -0.1335 | -0.1335 | 0.0333 | 1.43 | 0.0155 | -- | 3.63 | 84,862.57 | -5.16 | 5.21 | -5.90 | 6.53 | -- | -- | -333.47 | 265.77 | -- | -34.79 | 0.0479 | 0.00 | -10.18 | 43.86 | 16.85 | -- | 0.046 | -- |
Genus plc | 673.10m | 33.40m | 1.12bn | 3.48k | 33.64 | 1.95 | 14.56 | 1.67 | 0.5053 | 0.5053 | 10.18 | 8.71 | 0.6478 | -- | 6.03 | 193,642.10 | 2.90 | 3.58 | 3.30 | 4.20 | -- | -- | 4.47 | 5.44 | 1.40 | 5.44 | 0.3377 | 60.86 | 16.23 | 7.96 | -18.58 | 26.70 | 9.36 | 4.24 |
Worldwide Healthcare Trust PLC | -66.33m | -95.44m | 1.82bn | 0.00 | -- | 0.9919 | -- | -- | -0.1511 | -0.1511 | -0.1066 | 3.39 | -0.0288 | -- | -- | -- | -4.14 | 5.93 | -4.47 | 6.28 | -- | 86.25 | -- | 83.86 | -- | -- | 0.00 | 12.76 | 111.84 | -20.62 | 93.79 | -- | -- | 12.12 |
Holder | Shares | % Held |
---|---|---|
Invesco Asset Management Ltd.as of 31 Mar 2023 | 64.95m | 24.04% |
Lansdowne Partners (UK) LLPas of 31 Mar 2023 | 24.37m | 9.02% |
Baillie Gifford & Co.as of 31 Mar 2023 | 22.52m | 8.34% |
Jupiter Asset Management Ltd.as of 15 Jul 2020 | 14.25m | 5.27% |
M&G Investment Management Ltd.as of 31 Mar 2023 | 11.76m | 4.35% |
Miller Value Partners LLCas of 31 Mar 2021 | 10.04m | 3.71% |
Patient Capital Management, Inc.as of 31 Mar 2023 | 9.81m | 3.63% |
Eurizon Capital SGR SpAas of 02 Apr 2024 | 9.56m | 3.54% |
The Vanguard Group, Inc.as of 02 Apr 2024 | 6.60m | 2.44% |
Canaccord Genuity Asset Management Ltd.as of 07 Oct 2022 | 5.34m | 1.98% |